LIFESTANCE HLTH.GRP -,01 Aktie

Lifestance Health Group shares fall about 3.9% in premarket trading after the announcement that existing shareholders intend to sell 22,250,000 shares in a secondary placement. Barclays is acting as sole underwriter; LifeStance itself is issuing no new shares and will receive no proceeds from the transaction. The company also approved a conditional buyback of 2,000,000 shares at the same price as the underwriter, but the buyback is contingent on the placement closing. The combination of the large sell volume and a weak overall market pushes the price down to $12.30 and intensifies the negative market reaction. » Mere på de.investing.com

LifeStance has set the price for a secondary placement of 22,250,000 common shares at $12.35 per share. The company itself is not selling any shares and will receive no proceeds; the proceeds will go to the selling shareholders. LifeStance may optionally purchase 2,000,000 shares from the underwriter at the same price; closing of the transaction is expected on September 11, 2026, and Barclays is acting as underwriter. » Mere på de.investing.com

Lifestance Health Group’s stock rose to a 52‑week high of $12.97 and trades around $13, implying a market cap of about $4.81 billion and a 129.51% gain over the past year. For Q2 2026 the company reported adjusted EPS of $0.06 and revenue of $435.35 million, both above analyst expectations, and raised its full‑year guidance. 26% revenue growth, an increase in adjusted EBITDA margin to 15.2% and 2.6 million visits (+19%) contributed to the positive reaction, while an InvestingPro analysis still rates the stock as slightly overvalued despite a low PEG of 0.23. » Mere på de.investing.com